Tag Archives: Cabometyx

May, 2018

December, 2017

August, 2017

February, 2017

April, 2016

  • 26 April

    Exelixis’ Renal Cell Carcinoma Drug Receives FDA Approval

    SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX™ (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. RCC is the most common form of kidney cancer in adults. …